Nov. 3, 2015
Researchers at the University of Nebraska—Lincoln have identified a novel biomarker of prostate cancer progression.
Androgen Deprivation therapy (ADT) is commonly prescribed to intermediate/high risk prostate cancer patients. However, a significant portion of patients stop responding to ADT and develop castration-resistant prostate cancer (CRPC). The enzyme UDP-Glucose Dehydrogenase (UGDH) is involved in the generation of precursors that drive the removal of androgens. University of Nebraska—Lincoln researchers, Melanie Simpson and Joe Barycki, have identified UGDH as a relevant biomarker for identifying patients that are likely to fail ADT, potentially leading to altered treatment decisions.
UGDH was quantified in a microarray of human core biopsy samples and the differential expression of UGDH in the tumor relative to the surrounding tissue was indicative of tumor response to therapy.
Wei, Q., Galbenus, R., Raza, A., Cerny, R. L., and Simpson, M. A. (2009) Androgen-Stimulated UDP-Glucose Dehydrogenase Expression Limits Prostate Androgen Availability without Impacting Hyaluronan Levels .Cancer Research69, 2332-2339
• Prognostic diagnostic - UGDH expression pattern can be used to predict a patient’s response to ADT
• Companion diagnostic - UGDH expression pattern can be used to select a patient population that will respond to UGDH inhibitors ( Tech 2303 )
• Simple – fits well within the current clinical workflow in a pathology lab.
• Informative – can be used to predict prognosis of patients as well as select a patient population for a novel therapy.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
enzyme udp-glucose dehydrogenase
altered treatment decisions
impacting hyaluronan levels
prostate cancer progression
patients stop responding
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium